Alopexx, Inc.
NASDAQ: ALPX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel R. Vlock
- Headquarters
- Cambridge, United States
- IPO year
- 2022
- Market cap
- $79.0
- Website
- https://www.alopexx.com
Loading ALPX…
Loading profile data…Frequently asked questions about ALPX
What does Alopexx, Inc. (ALPX) do?
Alopexx, Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializes in developing innovative immune-based treatments. The company's mission is to prevent, treat, and mitigate a range of bacterial, fungal, and parasitic infections. Its leading development candidates include Vaccine AV0328, a synthetic poly N-acety...
Where does ALPX trade?
Alopexx, Inc. (ALPX) trades on the NASDAQ.
What sector is ALPX in?
Alopexx, Inc. (ALPX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alopexx, Inc.?
Daniel R. Vlock is the chief executive officer of Alopexx, Inc. (ALPX).
Where is Alopexx, Inc. headquartered?
Alopexx, Inc. is headquartered in United States.
Does ALPX pay a dividend?
Alopexx, Inc. (ALPX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALPX go public?
Alopexx, Inc. (ALPX) completed its initial public offering in 2022.